Inmune Bio Shares Rise 0.63% to $1.46, Outperforming Peers
Inmune Bio’s stock edged up 0.63% to $1.46, trading below its 200‑day MA while peers fluctuate; explore its biotech outlook, recent moves, and market context.
3 minutes to read
INMUNE BIO INC
Inmune Bio’s Ebstrocel Deal & UK Filing Propel Cell Therapy to Market – Market Update
Inmune Bio’s Ebstrocel shows early safety and symptom‑relief, with a new UK filing and US licensing on the way – a key step toward market approval.
2 minutes to read